Biomea Fusion Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II ...
Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B, measured during oral glucose tolerance testing (OGTT),
Source: eagletribune.com